At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AGIO Agios Pharmaceuticals
Pre-Market Trading 05-14 07:17:27 EDT
33.54
+0.54
+1.64%
High33.66
Low32.77
Vol560.37K
Open33.40
D1 Closing33.00
Amplitude2.70%
Mkt Cap1.90B
Tradable Cap1.62B
Total Shares56.77M
T/O18.72M
T/O Rate1.16%
Tradable Shares48.26M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Earnings Beat: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.